

Patient Journey for FLUMIST® (Influenza Vaccine Live, Intranasal) Ordering, Shipping & At-Home Administration

1 Finding Out & Learning More About FLUMIST

FLUMIST AstraZeneca website

Includes educational
resources & support¹



Flumist.com




ASPN website

Third-party website that supports
FLUMIST home service²

2 Ordering Through Online Pharmacy

Adult completes a digital form to **determine eligibility**²



Medical Questionnaire
Please answer the following questions to see if FluMist is right for you and everyone you are ordering for.

1. Does anyone have any government insurance?
Government insurance is any state or federally funded insurance...[Show more](#) ▼

3 Confirming Eligibility

Online HCP reviews the form, **confirms eligibility** and generates and fills prescription²

-  **Commercial insurance for the 2025/26 season**
Only private health insurance
 -  **Age³**
2–49 years
 -  **Medical eligibility²**
ACIP Recommendations
- Pharmacist is available** via chat or a **toll-free number** for questions,² as per Immunize.org **FLUMIST screening tool**³

4 Shipping & Delivery

Shipped under **conditions** to maintain appropriate temperature²

Patients will receive **tracking updates** and/or **delivery notifications** via text/email²



FLUMIST is delivered on the date selected by the patient²



5 Handling & Administration



Additional resources:²



INDICATION

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

IMPORTANT SAFETY INFORMATION

- Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
- When administered in a healthcare setting, appropriate medical treatment must be immediately available to manage potential anaphylactic reactions. When self-administered or administered by a caregiver, immediate medical attention should be sought if the vaccine recipient experiences symptoms of an allergic reaction

Please see additional Important Safety Information on next page and full [Prescribing Information](#), including [Patient Information](#) and [Instructions for Use](#).

Patient Journey for FLUMIST® (Influenza Vaccine Live, Intranasal) Ordering, Shipping & At-Home Administration



6 Disposal of FLUMIST Sprayer & Packaging



After administration, the **single-use FLUMIST** sprayer(s) should be sent back using the **prepaid return envelope** included in the packaging²

Reporting Vaccination Status Through Immunization Information Systems (IIS)

Adult confirms administration of the vaccine. Pharmacy then reports vaccination to IIS.^{2,4,5}



Adult



ASPN website



Reporting service



Registries



CDC Dashboard

Documentation is available to patients and their health care providers^{2,a}

IMPORTANT SAFETY INFORMATION (continued)

- In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
- Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
- If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of potential benefits and risks
- The effectiveness of FLUMIST has not been studied in immunocompromised persons
- The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
- FLUMIST may not protect all individuals receiving the vaccine
- The most common solicited adverse reactions ($\geq 10\%$ in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever $> 100^\circ\text{F}$ (children ages 2-6 years), and sore throat (adult ages 18-49 years)

INDICATION

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

You may report side effects related to AstraZeneca products

Please see full Prescribing Information, including Patient Information and Instructions for Use.

^aIf contact information provided.

ACIP = Advisory Committee on Immunization Practices; ASPN = Asembia Specialty Pharmacy Network; CDC = Centers for Disease Control and Prevention; HCP = healthcare professional.

1. FluMist website. Coming as soon as next year: the only at-home flu vaccine, delivered with FluMist Home. Updated November 2024. Accessed February 26, 2025. <https://www.flumist.com/>; 2. In House Data, AstraZeneca. DoF REF-263898; 3. Immunize.org. Screening checklist for contraindications to live attenuated intranasal influenza vaccination. August 13, 2024. Accessed February 26, 2025. https://www.immunize.org/wp-content/uploads/catg_d/p4067.pdf; 4. Centers for Disease Control and Prevention. Immunization Information Systems Resources. May 17, 2024. Accessed February 26, 2025. https://www.cdc.gov/iis/about/index.html#cdc_data_surveillance; 5. Centers for Disease Control and Prevention. Influenza vaccine administration and coverage by jurisdiction, children and adults, United States. February 19, 2025. Accessed March 13, 2025. <https://www.cdc.gov/fluview/dashboard/vaccine-administration-coverage-jurisdiction-iis.html>.

This product information is intended for US Health Care Professionals only.
FLUMIST is a registered trademark of the AstraZeneca group of companies.
©2025 AstraZeneca. All rights reserved. US-100969 Last Updated 5/25

